S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Shelling kills 1 in Ukraine; Russia wants nuke plant pledges
The Day of Financial Reckoning Is Near (Ad)
Is AMC Entertainment Pulling a Fast One on the APEs?
High oil prices help Saudi Aramco earn $88B in first half
Ship carrying grain for hungry Ethiopia leaves Ukraine
US Dollar Replaced By "Biden Bucks"? (Ad)
Here is a Simple 4 Stock Portfolio that Can Outperform the Market
Saudi oil company Aramco's half-year profits reach close to $88 billion after posting a 90% surge in second quarter
Saudi Aramco's profits already $88B as oil prices stay high
US Dollar Replaced By "Biden Bucks"? (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Shelling kills 1 in Ukraine; Russia wants nuke plant pledges
The Day of Financial Reckoning Is Near (Ad)
Is AMC Entertainment Pulling a Fast One on the APEs?
High oil prices help Saudi Aramco earn $88B in first half
Ship carrying grain for hungry Ethiopia leaves Ukraine
US Dollar Replaced By "Biden Bucks"? (Ad)
Here is a Simple 4 Stock Portfolio that Can Outperform the Market
Saudi oil company Aramco's half-year profits reach close to $88 billion after posting a 90% surge in second quarter
Saudi Aramco's profits already $88B as oil prices stay high
US Dollar Replaced By "Biden Bucks"? (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Shelling kills 1 in Ukraine; Russia wants nuke plant pledges
The Day of Financial Reckoning Is Near (Ad)
Is AMC Entertainment Pulling a Fast One on the APEs?
High oil prices help Saudi Aramco earn $88B in first half
Ship carrying grain for hungry Ethiopia leaves Ukraine
US Dollar Replaced By "Biden Bucks"? (Ad)
Here is a Simple 4 Stock Portfolio that Can Outperform the Market
Saudi oil company Aramco's half-year profits reach close to $88 billion after posting a 90% surge in second quarter
Saudi Aramco's profits already $88B as oil prices stay high
US Dollar Replaced By "Biden Bucks"? (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Shelling kills 1 in Ukraine; Russia wants nuke plant pledges
The Day of Financial Reckoning Is Near (Ad)
Is AMC Entertainment Pulling a Fast One on the APEs?
High oil prices help Saudi Aramco earn $88B in first half
Ship carrying grain for hungry Ethiopia leaves Ukraine
US Dollar Replaced By "Biden Bucks"? (Ad)
Here is a Simple 4 Stock Portfolio that Can Outperform the Market
Saudi oil company Aramco's half-year profits reach close to $88 billion after posting a 90% surge in second quarter
Saudi Aramco's profits already $88B as oil prices stay high
US Dollar Replaced By "Biden Bucks"? (Ad)
NASDAQ:AKUS

Akouos - AKUS Stock Forecast, Price & News

$3.12
+0.29 (+10.25%)
(As of 08/12/2022 09:14 PM ET)
Add
Compare
Today's Range
$2.87
$3.24
50-Day Range
$2.60
$5.20
52-Week Range
$2.32
$13.69
Volume
100,500 shs
Average Volume
229,597 shs
Market Capitalization
$108.03 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$18.00

Akouos MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
476.9% Upside
$18.00 Price Target
Short Interest
Bearish
12.11% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.87mentions of Akouos in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.96) to ($2.42) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.21 out of 5 stars

Medical Sector

522nd out of 1,135 stocks

Pharmaceutical Preparations Industry

262nd out of 557 stocks

AKUS stock logo

About Akouos (NASDAQ:AKUS) Stock

Akouos, Inc., a precision genetic medicine company, developing gene therapies to restore, improve, and preserve physiologic hearing for individuals. The company's precision genetic medicine platform incorporates a proprietary adeno-associated viral vector library and a novel delivery approach. Its lead product candidate is AK-OTOF, a gene therapy for the treatment of hearing loss due to mutations in the OTOF gene. The company is also developing AK-CLRN1 for the auditory manifestations of Usher syndrome 3A, or USH3A; and AK-antiVEGF for vestibular schwannoma. In addition, its precision genetic medicine platform addresses hearing loss related to genes needed for supporting cell function. The company was incorporated in 2016 and is based in Boston, Massachusetts.

Analyst Ratings Changes

Separately, Piper Sandler cut their price objective on shares of Akouos from $40.00 to $18.00 and set an "overweight" rating on the stock in a report on Tuesday, May 17th.

Akouos Price Performance

AKUS Stock traded up $0.29 on Friday, reaching $3.12. 100,506 shares of the company traded hands, compared to its average volume of 100,721. The firm has a fifty day simple moving average of $3.65 and a 200-day simple moving average of $4.05. The company has a market cap of $108.05 million, a P/E ratio of -1.10 and a beta of -0.01. Akouos has a one year low of $2.32 and a one year high of $13.69.

Akouos (NASDAQ:AKUS - Get Rating) last released its earnings results on Thursday, May 12th. The company reported ($0.78) EPS for the quarter, missing analysts' consensus estimates of ($0.73) by ($0.05). On average, sell-side analysts forecast that Akouos will post -2.96 EPS for the current year.

Receive AKUS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Akouos and its competitors with MarketBeat's FREE daily newsletter.

AKUS Stock News Headlines

27 U.S. Cities Where Stocks Yield 26% a Year
What’s the highest-yielding stock you’ve ever owned? The dividends for these stocks have risen so fast over the years that they’re now yielding us an average of 26%! When you start getting paid 26% on your money, your financial problems tend to pretty much evaporate. pixel
Potential 500% Return From A Unique $1 Asset?
Millions are rushing towards life at “Ground Zero”.  A frightening new financial reality that has the potential to erase the wealth of millions. It’s largely avoidable if you know what to look for. It all hinges on a single $1 asset that skyrockets during strange times like these.  Discover it now pixel
See More Headlines
Receive AKUS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Akouos and its competitors with MarketBeat's FREE daily newsletter.

AKUS Company Calendar

Last Earnings
11/12/2021
Today
8/14/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AKUS
Fax
N/A
Employees
103
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$18.00
High Stock Price Forecast
$18.00
Low Stock Price Forecast
$18.00
Forecasted Upside/Downside
+476.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-86,670,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$6.77 per share

Miscellaneous

Free Float
32,964,000
Market Cap
$108.03 million
Optionable
Not Optionable
Beta
-0.01

Key Executives

  • Dr. Emmanuel Simons M.B.A. (Age 39)
    Ph.D., Co- Founder, Pres, CEO & Director
    Comp: $790.72k
  • Dr. Michael John McKenna M.D. (Age 65)
    Co-Founder, Chief Medical Officer & Member of Scientific Advisory Board
    Comp: $539.35k
  • Ms. Jennifer Anne Wellman M.S. (Age 44)
    Chief Operating Officer
    Comp: $568.67k
  • Dr. Luk H. Vandenberghe M.D.
    Ph.D., Founder & Member of Scientific Advisory Board
  • Mr. William F. Sewell Ph.D.
    Founder & Member of Scientific Advisory Board
  • Mr. Richard Smith M.D.
    Founder & Member of Scientific Advisory Board
  • Ms. Sachiyo Minegishi (Age 44)
    CFO, Treasurer, Assistant Sec. & Principal Accounting Officer
  • Ms. Stacy Price
    Chief Technical Officer
  • Dr. Aaron Tward M.D.
    Ph.D., Chief Scientific Officer
  • Dr. Karoline K. Shair
    Sr. VP, Gen. Counsel, Chief Legal Officer & Corp. Sec.













AKUS Stock - Frequently Asked Questions

Should I buy or sell Akouos stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Akouos in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" AKUS shares.
View AKUS analyst ratings
or view top-rated stocks.

What is Akouos' stock price forecast for 2022?

1 analysts have issued 1 year target prices for Akouos' shares. Their AKUS share price forecasts range from $18.00 to $18.00. On average, they anticipate the company's share price to reach $18.00 in the next twelve months. This suggests a possible upside of 476.9% from the stock's current price.
View analysts price targets for AKUS
or view top-rated stocks among Wall Street analysts.

How have AKUS shares performed in 2022?

Akouos' stock was trading at $8.50 at the beginning of 2022. Since then, AKUS stock has decreased by 63.3% and is now trading at $3.12.
View the best growth stocks for 2022 here
.

How were Akouos' earnings last quarter?

Akouos, Inc. (NASDAQ:AKUS) issued its earnings results on Friday, November, 12th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.63) by $0.04.

What other stocks do shareholders of Akouos own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Akouos investors own include NVIDIA (NVDA), Honeywell International (HON), QUALCOMM (QCOM), Raytheon Technologies (RTX), CVS Health (CVS), Johnson & Johnson (JNJ), Cisco Systems (CSCO), Home Depot (HD), Pfizer (PFE) and Procter & Gamble (PG).

When did Akouos IPO?

(AKUS) raised $124 million in an IPO on Friday, June 26th 2020. The company issued 8,300,000 shares at $14.00-$16.00 per share. BofA Securities, Cowen and Piper Sandler served as the underwriters for the IPO and BTIG was co-manager.

What is Akouos' stock symbol?

Akouos trades on the NASDAQ under the ticker symbol "AKUS."

Who are Akouos' major shareholders?

Akouos' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include JPMorgan Chase & Co. (0.59%), Capital Wealth Alliance LLC (0.29%), Renaissance Technologies LLC (0.26%), Northern Trust Corp (0.12%), Gladius Capital Management LP (0.02%) and Concourse Financial Group Securities Inc. (0.00%).

How do I buy shares of Akouos?

Shares of AKUS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Akouos' stock price today?

One share of AKUS stock can currently be purchased for approximately $3.12.

How much money does Akouos make?

Akouos (NASDAQ:AKUS) has a market capitalization of $108.05 million. The company earns $-86,670,000.00 in net income (profit) each year or ($2.83) on an earnings per share basis.

How many employees does Akouos have?

The company employs 103 workers across the globe.

How can I contact Akouos?

Akouos' mailing address is 645 SUMMER STREET SUITE 200, BOSTON MA, 02210. The official website for the company is www.akouos.com. The company can be reached via phone at 857-410-1818 or via email at turiano@sternir.com.

This page (NASDAQ:AKUS) was last updated on 8/15/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.